Bone marrow adipose tissue, bone marrow adipocytes, white adipose tissue, brown adipose 33 tissue, beige adipose tissue, PET/CT, glucose homeostasis, insulin, cold exposure, bone 34 1 HIGHLIGHTS 35 36 • Bone marrow adipose tissue (BMAT) is molecularly distinct to other adipose 37 subtypes. 38 • BMAT is less insulin responsive than WAT and, unlike BAT, is not cold-responsive. 39 • Human BMAT has greater basal glucose uptake than axial bone or subcutaneous 40 WAT.
not enriched for brown or beige adipocyte markers. Instead, pathway analysis indicated 48 altered glucose metabolism and decreased insulin responsiveness in BMAT. We therefore 49 tested these functions in mice and humans using positron emission tomography-computed 50 tomography (PET/CT) with 18 F-fluorodeoxyglucose, including establishing a new method for 51 BMAT identification from clinical CT scans. This revealed that BMAT resists insulin-and 52 cold-stimulated glucose uptake and is thus functionally distinct to WAT and BAT. However, 53 BMAT displayed greater basal glucose uptake than axial bones or subcutaneous WAT, 54 underscoring its potential to influence systemic glucose homeostasis. These PET/CT 55 studies are the first to characterise BMAT function in vivo and identify BMAT as a distinct, 56 major subtype of adipose tissue. 57 
INTRODUCTION
produce adipokines such as leptin and adiponectin (Sulston and Cawthorn, 2016) and can 110 release free fatty acids in response to lipolytic stimuli, albeit to a lesser extent than WAT 111 (Scheller et al., 2018; Tran et al., 1981) . This lipolysis resistance is more pronounced for 112 rBMAds, underscoring the functional differences in BMAd subtypes. 113 114 Despite these advances in understanding of BMAT lipid metabolism, its insulin 115 responsiveness and role in systemic glucose homeostasis is poorly understood. PET/CT 116 studies have demonstrated glucose uptake into whole bones or BM of animal models and 117 humans (Huovinen et al., 2016; Huovinen et al., 2014; Nishio et al., 2012; Zoch et al., 2016) , 118 but uptake specifically into BMAT has not previously been examined. Whether BMAT is 119 BAT-or beige-like is also debated (Scheller et al., 2016) . UCP-1 positive adipocytes have 120 been noted in vertebral BM of a young mouse (Nishio et al., 2012) and as an incidental 121 finding in one clinical case study (Chapman and Vega, 2017) , but most studies find very low 122 skeletal UCP-1 expression (Krings et al., 2012; Sulston et al., 2016) . It has been suggested 123 that BMAT is BAT-like, albeit based only on transcript expression from whole bones (Krings 124 et al., 2012) . Notably, no studies have fully investigated if BMAT has properties of BAT or 125 beige fat in vivo. Together, it remains unclear if BMAT performs metabolic functions similar 126 to WAT, BAT or beige adipose tissue. 127 128 Herein, we used transcriptomic analysis and 18 F-FDG PET/CT to address these 129 fundamental gaps in knowledge and thereby determine if, in vivo, BMAT has metabolic 130 functions of WAT or BAT. Our studies in animal models and humans demonstrate that BMAT 131 is transcriptionally and functionally distinct to WAT, BAT and beige adipose tissue, 132 identifying BMAT as a unique class of adipose tissue. We show that BMAT has greater basal 133 glucose uptake than WAT and establish methods for BMAT characterisation by PET/CT. 134 Together, this knowledge underscores the potential for BMAT to influence metabolic 135 homeostasis and sets a foundation for future research to reveal further roles of BMAT in 136 normal physiology and disease. 137 138 139 BMAT is transcriptionally distinct to WAT, BAT and beige adipose tissues 140 The functional hallmarks of WAT, BAT and beige adipose tissue are reflected on a molecular 141 level, with each class having distinct transcriptomic profiles and characteristic marker genes 142 (Rosell et al., 2014; Svensson et al., 2011; Wu et al., 2012) . Thus, to test if BMAT has distinct 143 metabolic functions, we first compared the transcriptomes of whole BMAT and WAT from 144 two cohorts of rabbits. Principle component analysis of both cohorts identified BMAT as a 145 distinct depot compared to gonadal WAT (gWAT) and inguinal WAT (iWAT) (Fig. 1A) ; 146 however, BMAT from either rabbit cohort was not uniformly enriched for markers of brown 147 or beige adipocytes (Fig. 1B, S1A ): although SLC27A2 was significantly higher in BMAT 148 than WAT from both cohorts, and PPARGC1A in BMAT from cohort 1, several other brown 149 and/or beige markers were more highly expressed in WAT, while most such markers were 150 not differentially expressed between BMAT and WAT in either cohort (Fig. 1B, S1A ). Thus, 151 the transcriptomic distinction with WAT is not a result of BMAT being more brown-or beige-152 like. Instead, gene set enrichment analysis (GSEA) highlighted the potential for BMAT to 153 have altered glucose metabolism and decreased insulin responsiveness compared to WAT 154 ( Fig. 1C,1D , S1B). 155 156 To determine if similar differences occur in humans, we next analysed the transcriptomes of 157 adipocytes isolated from human femoral BMAT and subcutaneous WAT, which our previous 158 analyses revealed to be globally distinct (Mattiucci et al., 2018) . Consistent with our findings 159 in rabbits, human BMAds were not enriched for brown or beige markers and had decreased 160 expression of genes relating to glucose metabolism and insulin responsiveness ( Fig. 1E,   161 S2A, S2B). To further address this we next pursued targeted analysis of adipocytes isolated 162 from BM and WAT of a second cohort of subjects; we also isolated adipocytes from 163 trabecular bone (Bone Ads) to assess potential site-specific differences in BMAd function 164 (Craft et al., 2018) . Adipocyte purity was confirmed histologically (data not shown) and by 165 qPCR (Fig. S2C) . In situ, these BM and bone adipocytes resembled unilocular white 166 adipocytes (Fig. 1F) ; however, qPCR revealed significant differences in transcript 167 expression of INSR, IRS1, IRS2, SLC2A4, SLC2A1 and SLC2A3 between WAT adipocytes 168 and those from BM or bone (Fig. 1G) . Notably, compared to white adipocytes, each BMAd 169 subtype had decreased SLC2A4 and increased SLC2A1 and SLC2A3, suggesting that 170 BMAds may have higher basal glucose uptake that is less insulin responsive. In contrast, 171 there were no differences in expression of UCP1, and most other brown or beige adipocyte 172 markers were not enriched in either BMAd subtype ( Fig. 1G, S2D ). 173 174 Taken together, these data demonstrate that BMAds in animal models and humans are 175 transcriptionally distinct to white, brown and beige adipocytes, and suggest altered roles in 176 systemic glucose homeostasis and insulin responsiveness. 179 To test the metabolic functions of BMAT in vivo we used 18 F-FDG PET/CT in mice to 180 determine if, like WAT, BMAT is insulin-responsive. As expected, insulin decreased blood 181 glucose ( Fig. 2A ) and increased 18 F -FDG uptake in the heart, iWAT and gWAT ( Fig. 2B , C 182 and F). To assess 18 F-FDG uptake separately within bone and BMAT, we first applied 183 thresholding to the PET/CT data to separate bone from BM based on their different tissue 184 densities (data not shown). This revealed that insulin significantly increased 18 F -FDG uptake 185 in femoral bone, whereas humoral bone uptake decreased; uptake in proximal or distal tibial 186 bone was unaffected ( Fig. 2F ). To assess BMAT-specific 18 F-FDG uptake we took 187 advantage of the regional differences in BMAT content around the mouse skeleton. Thus, 188 adipocytes comprise only a small percentage of total BM volume of humeri, femurs and 189 proximal tibiae, but predominate in distal tibiae ( Fig. 2E ). To address the contribution of 190 BMAT to skeletal 18 F-FDG uptake, we therefore quantified 18 F-FDG in a bone-region-specific 191 manner to distinguish between areas of low BMAT (humerus, femur, proximal tibia) and high 192 BMAT (distal tibia). This revealed that insulin did not significantly affect glucose uptake in 193 any of the BM regions analysed (Fig. 2F ). Thus, compared to WAT, BM and BMAT resist 194 insulin-stimulated glucose uptake. 195 196 Cold exposure in mice does not induce glucose uptake or beiging in BMAT 197 To test if BMAT is BAT-or beige-like in vivo, we next analysed 18 F-FDG uptake following 198 acute or chronic cold exposure in mice ( Fig. S3A ). Acute (4 h) or chronic cold (72 h) 199 increased energy expenditure without causing weight loss or hypoglycaemia ( Fig. S3B-D) , 200 likely due to increased food consumption in chronic cold mice ( Fig. S3E ). BAT 18 F-FDG 201 uptake increased after either duration of cold ( Fig. 3A-C ). Chronic cold also increased iWAT 202 18 F-FDG uptake, suggesting beiging of this depot (Fig. 3C ). However, neither acute nor 203 chronic cold exposure increased 18 F-FDG uptake into bone or BM ( Fig. 3B ). Indeed, cold 204 exposure decreased 18 F-FDG uptake into distal tibial BMAT, highlighting fundamental 205 differences with iWAT and BAT. Cold exposure also decreased BAT lipid content and 206 promoted beiging of iWAT, as indicated by formation of multilocular adipocytes, but these 207 effects did not occur in BMAT ( Fig. 3D ). Consistent with this, cold exposure induced brown 208 and beige transcripts in BAT and iWAT, but not within bone ( Fig. 3E 216 We next tested if these distinct metabolic properties extend to BMAT in humans. First, we 217 established a method to identify BMAT from clinical PET/CT scans. To determine Hounsfield 218 Units (HU) for BMAT, we identified BMAT-rich and BMAT-deficient BM regions by magnetic 219 resonance imaging (MRI). This revealed that sternal BM is BMAT-enriched while vertebral 220 BM is BMAT-deficient ( Fig. 4A) ; WAT was also analysed as an adipose-rich control region. 221 We then co-registered the MRI data with paired CT scans of the same subjects ( Fig. 4A) . 222 This revealed a distinct HU distribution for BMAT-rich sternal BM, intermediate between 223 WAT and red marrow (RM) of BMAT-deficient vertebrae (Fig. 4B ).
RESULTS
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Insulin treatment in mice does not induce glucose uptake in BMAT
CT-based identification of BMAT in humans
225
Using these distinct HU distributions, we generated a receiver operating characteristic 226 (ROC) curve to identify optimal diagnostic HU thresholds to distinguish BMAT from RM (Fig. 227 S4A). This revealed that BMAT-rich BM has HU <115, whereas RM is mostly within 115-228 300 HU (Fig. 4B ); bone was defined as >300 HU. To test the validity of these thresholds we 229 applied them to clinical CT data to determine BMAT volume as % BM volume. We found 230 that BMAT predominated in the arms, legs and sternum but was markedly lower in the 231 clavicle, ribs and vertebrae ( Fig. 4C, Fig. S4B ). Moreover, %BMAT showed age-associated 232 increases in the axial skeleton but not in long bones (Fig. S4B ). These data are consistent 233 with previous studies showing that BMAT predominates in the long bones by early adulthood 234 but continues to accumulate in axial bones beyond 60 years of age (Baum et al., 2018; 235 Kricun, 1985; Schraml et al., 2015) . Together, this supports the validity of our CT thresholds 236 for BMAT identification in humans.
238 239 240
Human BMAT is functionally distinct to BAT and is a major site of basal glucose 241 uptake 242 We then applied these thresholds to human co-registered PET/CT data to assess 18 F-FDG 243 uptake in BMAT, RM and bone. To test if BMAT is BAT-like we first compared BMAT 18 F-244 FDG uptake between three groups: subjects with no detectable supraclavicular BAT at room 245 temperature (No BAT), subjects with active BAT at room temperature (Active BAT), and 246 cold-exposed subjects (16 ºC for 2 h; Cold). PET/CT confirmed BAT 18 F-FDG uptake in the 247 latter two groups but not in the No BAT group ( Fig. 4D-E, Fig. S4C ). Cold exposure did not 248 alter 18 F-FDG uptake in scWAT but was associated with increased uptake in sternal and 249 clavicular bone tissue; however, these were the only skeletal sites at which 18 F-FDG uptake 250 significantly differed between the No BAT, Active BAT and Cold subjects ( Fig. 4E, Fig. S4D ). 251 Indeed, the Active BAT and Cold subjects did not have increased glucose uptake in BMAT 252 or RM of any bones analysed ( Fig. 4E, Fig. S4D ). Thus, consistent with our findings in mice, 253 BMAT glucose uptake in humans is not cold-responsive.
255
Our previous human PET/CT studies revealed that glucocorticoids acutely activate BAT 256 (Ramage et al., 2016a) . Glucocorticoids also promote BMAT accumulation, demonstrating 257 that BMAT can be glucocorticoid-responsive (Scheller et al., 2016) . Thus, to further test if 258 BMAT shares properties of BAT, we analysed PET/CT data from previously reported 259 subjects (Ramage et al., 2016a) to determine if glucocorticoids also influence glucose 260 uptake in human BMAT. We found that prednisolone significantly influenced 18 F-FDG uptake 261 only in vertebrae, in which there was a trend for increased uptake into RM but not BMAT or 262 bone ( Fig. S4E ). However, prednisolone did not influence 18 F-FDG uptake at any other site. 263 Thus, unlike BAT, BMAT glucose uptake is not glucocorticoid-responsive.
265
The above findings confirm that, in humans, BMAT is functionally distinct to BAT. However, 266 while analyzing these data, two other phenomena became apparent. Firstly, within axial 267 bones of each subject, BMAT had significantly higher glucose uptake than bone ( Fig. 4F ). 268 In the sternum, glucose uptake was also greater in BMAT than in RM ( Fig. 4F ). Secondly, 269 BMAT at each skeletal site had higher glucose uptake than scWAT ( Fig. 4G ). Thus, despite 270 being unresponsive to insulin or activators of BAT, BMAT has high basal glucose uptake, 271 highlighting its potential to influence systemic glucose homeostasis. 273 274 Unlike WAT and BAT, the role of BMAT in systemic energy metabolism is poorly understood. 275 Previous studies have shed some light on BMAT lipid metabolism in vivo (Scheller et al., 276 2018; Tran et al., 1981) , and PET/CT has been used to assess glucose uptake into bones 277 or BM (Huovinen et al., 2016; Huovinen et al., 2014; Nishio et al., 2012; Zoch et al., 2016) ; 278 however, our study is the first to characterise in vivo glucose metabolism specifically in 279 BMAT. Our data provide key insights into how BMAT compares to WAT and BAT; reveal 280 new site-specific differences in BMAT characteristics; and identify BMAT as a major site of 281 skeletal glucose disposal. Moreover, we establish a method for BMAT identification and 282 analysis by PET/CT that will open new avenues for future study of BMAT function.
272
DISCUSSION
284
We show, for the first time, that, compared to WAT, BMAT resists insulin-stimulated glucose 285 uptake. This is supported not only by PET/CT of mouse distal tibial BMAT, but also by the (Liu et al., 2011) . These data are strikingly consistent with our results for transcript 301 expression in rabbits and humans ( Fig. 1, Fig. S1 -2) and further support the conclusion that, 302 compared to WAT, BMAT resists insulin-stimulated glucose uptake. 303 304 In addition to BMAT, we also found that insulin responsiveness varies among different 305 bones: in insulin-treated mice, bone glucose uptake increases in femurs, decreases in 306 humeri and is unaltered in tibiae. In contrast, Zoch et al report that insulin stimulates 18 F-307 FDG uptake into whole femurs and tibiae (Zoch et al., 2016) . This discrepancy may relate 308 to technical differences: Zoch et al analysed whole bones (including BM) of anesthetised 309 mice, whereas we distinguished between bone and BM and avoided anaesthesia. It is 310 unclear why insulin is associated with decreased glucose uptake in humeral bone and BM; 311 this is unlikely to be a technical issue given that we see expected insulin-stimulated glucose 312 uptake in the heart, WAT and femur. Thus, the lack of increases in humeri and tibiae 313 suggests that there are site-specific differences in skeletal insulin responsiveness.
315
Another major finding is that BMAT is molecularly and functionally distinct to brown and 316 beige adipose tissues, both for cBMAT of mice and rabbits, and for rBMAT of humans at 317 multiple skeletal sites. These molecular distinctions are consistent with several other 318 studies. We and others previously found that tibial Ucp1 expression is over 10,000-fold lower 319 than in BAT (Krings et al., 2012; Sulston et al., 2016) , consistent with our present finding 320 that Ucp1 is undetectable in whole mouse bones. Similarly, microarrays show that UCP1 is 321 not enriched in whole BM of mice or humans (Dezso et al., 2008; Thorrez et al., 2008) , nor 322 is it greater in BMAds vs white adipocytes of mice (Liu et al., 2011) . Moreover, BMAd 323 progenitors are more white-like than brown-like and do not express brown adipocyte 324 markers after adipogenesis in vitro (Ambrosi et al., 2017) . However, despite these diverse lines of evidence to the contrary, the concept that BMAT may be BAT-or beige-like has 326 persisted. Thus, our in vivo functional analyses of mice and humans are a key advance 327 because they confirm that cold exposure does not induce glucose uptake or beiging in 328 BMAT. This demonstrates, conclusively, that BMAT is not BAT-or beige-like. 329 330 Our glucocorticoid studies provide further insights. Unlike in BAT, acute glucocorticoid 331 treatment in humans does not stimulate glucose uptake in BMAT; however, it does influence 332 uptake across lumbar vertebrae, with a trend for increases in RM ( Fig. S4E ). It is notable 333 that this occurs only in vertebrae, because these are also the bones in which glucocorticoids 334 drive the greatest increases in fracture risk (Briot and Roux, 2015) . This raises the possibility 335 that glucocorticoids modulate BM and bone metabolism in a site-specific manner and that 336 these metabolic effects contribute to glucocorticoid-induced osteoporosis. Future studies 337 using different doses and durations of glucocorticoids would further elucidate their ability to 338 modulate metabolism of RM, BMAT and bone, and whether this influences glucocorticoid-339 induced osteoporosis.
341
Although BMAT glucose uptake is not stimulated by insulin at physiological concentrations, 342 cold exposure or glucocorticoids, a major finding is that BMAT in humans has high basal 343 glucose uptake, exceeding that of WAT and greater than that for bone or RM in the axial 344 skeleton. Superficially, this seems at odds with two studies reporting that BM 18 F-FDG 345 uptake correlates inversely with BM fat content (Huovinen et al., 2014; Schraml et al., 2015) ; 346 however, on further consideration, it is clear that these findings are not inconsistent with 347 ours. Indeed, we show that axial bones have less BMAT but greater BM 18 F-FDG uptake 348 than humeri or femurs, mirroring these and other previous reports of 18 F-FDG uptake in 349 whole BM (Huovinen et al., 2016) . Importantly, unlike our approach, no previous studies 350 have distinguished 18 F-FDG uptake between RM and BMAT specifically. Thus, a unique 351 advance of our work is the finding that, in axial bones, BMAT glucose uptake is greater than 352 in bone and similar or greater than in RM. This is particularly notable given that both BM and 353 bone are sites of high glucose uptake, capable of exceeding levels observed in WAT or 354 skeletal muscle (Huovinen et al., 2016; Huovinen et al., 2014; Zoch et al., 2016) (Fig. 4, Fig. 355 S4). Indeed, bone glucose uptake is required for normal metabolic function (Li et al., 2016) . 356 Together, these observations support the conclusion that BMAT may influence systemic 357 glucose homeostasis. 358 359 We also reveal that BMAT glucose uptake varies at different skeletal sites, generally being 360 greater in axial BMAT compared to BMAT in long bones. This is consistent with depot-361 dependent differences in other BMAT characteristics and, broadly, with the concept that 362 BMAT exists in regulated and constitutive subtypes (Craft et al., 2018) . However, while axial 363 BMAT has higher glucose uptake, BMAT volume in peripheral bones is typically far higher 364 ( Fig. 4, Fig. S4 ) (Kricun, 1985 high expression of SLC2A1 and/or SLC2A3 (Fig. 1 ), a finding supported by previous 370 microarray studies (Liu et al., 2011) . Indeed, among numerous human tissues, SLC2A3 371 expression is highest in BM (Dezso et al., 2008) , while Slc2a3 is also greater in BM than in 372 WAT of mice (Thorrez et al., 2008) . Mouse BMAds also have a dense mitochondrial network 373 (Robles et al., 2018) and, by electron microscopy, we found that mitochondria are also 374 abundant in human BMAds (S. Cinti, personal communication). This supports the conclusion 375 that BMAds are metabolically active, which may further explain their high basal glucose 376 uptake.
378
Finally, we have developed a method to identify BMAT from CT scans, allowing its functional 379 analysis by PET/CT. At least one other study has used HU thresholding to try to distinguish 380 BMAT-enriched vs BMAT-deficient BM (Rantalainen et al., 2013) , but our method is more 381 comprehensive because we directly compared paired MRI and CT scans to identify the 382 optimal BMAT HU thresholds. The finding that the sternum is BMAT-rich was unexpected 383 as this contrasts with most other axial bones; however, it is consistent with adipogenic 384 progenitors being readily detectible within sternal BM (Ambrosi et al., 2017) . Otherwise, our 385 method identifies site-and age-dependent differences in RM and BMAT that are in full 386 agreement with previous studies (Baum et al., 2018; Kricun, 1985; Schraml et al., 2015) . 387 Applying our PET/CT approach to other clinical and preclinical studies, including 388 retrospectively, therefore holds great promise to reveal further physiological and 389 pathological roles of BMAT. Importantly, the diversity of PET tracers could extend such 390 studies far beyond glucose metabolism, allowing many other functions of BMAT to be 391 addressed. 392 393 In summary, this study is the first to dissect BMAT glucose metabolism in vivo and identifies 394 BMAT as a distinct, major subtype of adipose tissue. For human subjects in cohort 1 (Fig. 1E , Supplemental Fig. 2A-B After weighing, each tissue was minced in the petri dish using a sterile scalpel and scissors, 548 then transferred to a Falcon tube containing the collagenase solution. Tissues in 549 collagenase were then incubated for 45 min in a shaking water bath (120 rpm) at 37ºC. Next, 550 collagenase-digested tissue was passed through a 300 µm nylon filter and the cells within 551 the filtrate were washed with fresh KRH buffer. Samples were then centrifuged at 500 rcf for 552 5 min at 4ºC. The floating adipocyte layer was transferred by pipette to a new tube to be 553 used for RNA isolation; an aliquot was also analyzed histologically to confirm the presence 554 of adipocytes. After aspirating and discarding the supernatant, the stromal vascular fraction 555 (SVF) of cells within the pellet was resuspended in 2x volume of red blood cell lysis buffer 556 (Cat. No. R7757, Sigma) and incubated at room temperature for 5 min to lyse erythrocytes.
557
KRH buffer was added to bring the volume to 15 mL and samples were centrifuged at 700 558 rcf for 10 min at 4ºC. The SVF pellet was then used for RNA isolation. Hochberg approach to control for false discovery rate (Benjamini and Hochberg, 1995) . 578 For rabbit studies, purified RNA was digested on-column with DNase I and cleaned using 580 the Qiagen RNeasy kit (Qiagen, Valencia, CA, USA) as recommended by the manufacturer. 581 Total RNA was then submitted to the microarray core at the University of Michigan. The 582 samples were screened for quality and processed in the microarray facility using custom 583 rabbit Affymetrix arrays and the IVT Express kit (Affymetrix, Santa Clara, CA, USA). As a 584 QC measure, the distribution of probe intensities and the 5' to 3' degradation profiles were counts are therefore presented as % injected dose per g tissue (%ID/g). Frozen and fixed 648 tissues were analyzed separately and the average MBq for each tissue was then calculated. 648 Half of the dissected material was then snap frozen on dry ice and stored at -80ºC for 649 molecular analyses. The remaining half of the dissected material was placed into 10% 650 formalin and stored at 4ºC for histological analysis. PET/CT analysis was then done as 651 described below.
653
Mouse cold-exposure studies 654 The protocol is adapted from (Wang et al., 2012) , with a summary depicted in Supplemental 655 Figure 3A . For the acute and chronic cold exposure studies (Fig. 3, Supplemental Fig. 4B to be housed in standard cages at RT. All groups were fasted, with access to water, for 4 h 665 before administration of 18 F -FDG (such that Acute cold mice were fasted throughout their 4 666 h cold exposure). Cages of cold-exposed mice were stored on ice in a ventilated cooler for isolation and gamma counting were done as described above for the insulin-treatment 673 studies. PET/CT analysis was then done as described below. assess effects of cold exposure, subjects were exposed to a mild cold (16 ºC) for 2 h, as 700 described previously (Ramage et al., 2016b) . To assess effects of prednisolone treatment, 701 subjects were recruited to a double-blind, randomized crossover study, as described 702 previously (Ramage et al., 2016b Scheller, E.L., Cawthorn, W.P., Burr, A.A., Horowitz, M.C., and MacDougald, O.A. (2016) PRKACA  RPTOR  IRS2  PHKB  ADIPOQ  PRKAB1  SORT1  TBL1XR1  MAPK9  PPP1CC  PRKAR2B  PYGL  CBL  PRKAR2A  SOS1  CREBL2  TSC1  INSR  PTPN11  ARPP19  PRKACB  NUP43  CRK  NUP155  GSK3B  MTOR  MAPK1  GRB2  EXOC7  FLOT1  NUP88  PIK3R3  SLC2A6  SLC2A1  SLC2A3  RFX6  SLC2A2  PIK3R5  SLC2A12  HNF1A  DRD1  SLC2A7  G6PC  FBP2  SHC4  GCKR  AKT3  SLC2A13   FGF10  SLC2A10  PIK3R2  SLC2A8  SREBF1  PCK2  FASN  IRS1  SLC2A4  CEBPA  AACS  CAV2  RARRES2  AKT2  PCK1  PPP1CB  PPARG  PIK3R1  EIF4EBP2  PDE3B  DENND4C  FABP4  PIK3CA  SIRT1  PIK3CB  FLOT2  SESN2  PRKAG1  TSC2  POM121  MAPK3  MKNK2  CALM2  PRKAG2  TRIP10  SLC25A33  VAMP2  ARAF  ADIPOR2  INPP5K  LIPE  LEP  ACACB  SIK2  PYGB  CALM1  RAB4B Figures 1 and S1. (C,D) qPCR to validate purity of adipocytes isolated from each tissue (C) and showing that BM adipocytes generally do not have increased expression of brown or beige adipocyte markers (D). Transcript expression was normalized to expression of IPO8 (C) or RNA18SN5 (D). Data in (C) are mean ± SEM of the following numbers per group: BM Ads, n = 8 (ADIPOQ) or 9 (PPARG); BM SVF, n = 3 (ADIPOQ) or 5 (PPARG); WAT Ads, n = 10 (ADIPOQ and PPARG); WAT SVF, n = 5 (ADIPOQ and PPARG); Bone Ads and SVF, n = 7 (PPARG) or 3 (ADIPOQ). Data in (D) are mean ± SEM of the following numbers per group: BM Ads, n = 3-10; WAT Ads, n = 6-10; Bone Ads, n = 3-7. For each transcript, significant differences are indicated as for Figure 1 . Effects of cold exposure on energy expenditure (B), body mass (C), baseline blood glucose (D), 72 h food intake (E) and transcript expression in BAT, iWAT or whole femurs (F-H). In (E), Acute cold mice are not shown because they were fasted throughout cold exposure. (I) A separate cohort of mice was housed at thermoneutrality, 22 ºC or 4 ºC for 48 h. Expression of BAT or beige cold exposure markers was then determined by qPCR of whole femurs. ND = not detectable. In (F-I), transcript expression was normalized to expression of Rn18s (F,H,I) or Ppia (G); the latter was used for iWAT because in this tissue Rn18s, but not Ppia, showed significant regulation between the three groups. Data are shown as boxand-whisker plots (B-E) or as mean ± SEM (F-H) of 7-8 mice per group. In (I), data are mean ± SEM of 8-10 mice per group. Significant differences between groups are indicated by * (P <0.05), ** (P <0.01) or *** (P <0.001). (B) Quantification of BMAT in CT scans of male and female subjects aged <60 or >60 years. A HU threshold of <115 was used to identify BMAT voxels in BM of the indicated bones, and total BM volume was also determined. The proportion of the BM cavity corresponding to BMAT (Ad.V/Ma.V) was then calculated. Data are shown as box-and-whisker plots of the following numbers of subjects for each group: <60 years, n = 28 (humerus), 9 (femur), or 27 (clavicle, sternum and vertebrae); >60 years, n = 7 for each bone. Significant differences between <60 and >60 groups are indicated by ** (P <0.01). (C) Representative coronal PET/CT images of No BAT, Active BAT and Cold subjects. FDG uptake in BAT is evident in the Active BAT and Cold subjects (arrows). Femurs were not included in scans of the Cold group. (D) FDG uptake in bone tissue, RM and BMAT of the indicated bones. Data are shown as mean ± SEM of 8 (No BAT) or 7 (7 Active BAT, Cold) subjects per group. Significant differences between these groups No BAT, Active BAT and Cold groups are indicated by # (P <0.05). (E) Subjects were treated with prednisolone or placebo control prior to analysis of FDG uptake by PET/CT. Data are shown as paired individual values for each subject. For each skeletal site, the influence of treatment or tissue (bone, RM, BMAT), and interactions between these, were determined by 2-way ANOVA; P values are shown beneath the graph.
WAT vs BMAT
(Rabbit) 2 0 -2 STAT1 RAB10 HIF1A ANKRD26 NUCKS1 PRKAA1 PIK3CA IRS1 INPP5K VAMP2 DENND4C GOT1 ZNF106 SLC25A33 PDK4 EIF4EBP2 ENPP1 SIK2 CAV2 RFX6 CYB5R4 ADRA1B MCU ADIPOR2 ADGRF5 SLC2A1 SLC2A4
D
